The listing below shows our latest News Items and is updated regularly. If you wish to post a news item please select the 'Post News' button on the right. The displayed news feed starts on 1st August 2016. Older items can be found here.
Funding & Investment
Oxford Immunotec intends to use the net proceeds from the offering for working capital and general corporate purposes.
Read the rest of entry »
Beamline Diagnostics, developers of an innovative biopsy triaging system, founded by Dr. Liberty Foreman and Dr. Katherine Willetts, has closed a £650k investment round which was led by a syndicate of Angels in MedCity (AiMC) and other investors.
Innovation Forum Leaders Conference 2017 - 'Convergence in Bio-innovation' - 4-5 December 2017, Oxford
The Innovation Forum Leaders Conference 2017 will take place on 4th and 5th December in Oxford, UK and is an invitation only, world-leading conference supporting industry-academic collaborations and investment for early-stage ventures. Apply for an invitation. Our global conference will bring together over 400 delegates from the healthcare, biotechnology and life science sectors: Academics, start-ups, early stage ventures, SMEs, large pharmaceutical companies, prominent investors and top innovators. CEOs, prominent investors and top innovators will deliver keynote speeches and head discussions on the latest trends in therapeutics, cleantech and medtech as part of our 2-day extensive programme of presentations and workshops.
Exscientia, an innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is pleased to announce that it has agreed a strategic research collaboration, and licence option agreement with Sanofi in the high-interest area of metabolic disease.
Delivery of new therapies for metabolic disease (such as diabetes) is hampered by a paucity of single targets that are amenable to drug discovery. To address this challenge, Exscientia will apply its unique platform to identify and validate combinations of drug targets* that could work synergistically and be amenable to Exscientia’s powerful bispecific-small-molecule design strategy – where a small molecule is designed to be compatible with two distinct drug targets.
Starting with over a thousand disease-relevant target combinations, Exscientia will triage opportunities and prioritise those with promising bispecific binding potential. Target pairs fulfilling these initial tractability criteria will pa ...
Philadelphia, USA and Oxford, UK: Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the closing of its previously announced registered direct offering of its American Depositary Shares (“ADSs”) following its entry into a definitive agreement with Matrix Capital Management Company, LP (“Matrix”) to purchase an aggregate of approximately US$42,000,000 of its ADSs. Adaptimmune sold 7,000,000 ADSs at a price of $6.00 per ADS.
Glasgow, Scotland: MGB Biopharma, a biopharmaceutical company developing a novel class of anti-infectives to address the major global problem of antibiotic resistance, announces today that it has raised $1.15 million in a financing round with existing investors.
Following a £0.5m Medical Research Council (MRC) grant to implement new Positron Emission Tomography (PET) imaging tracers for mitochondrial dysfunction and synaptic loss, Imanova has been awarded an additional £1m of strategic funding from the MRC for clinical evaluation of this combination of tracers in Alzheimer’s disease and Parkinson’s disease - Stage 1 of the MIND-MAPS (Molecular Imaging of Neurodegenerative Disease – Mitochondria, Associated Proteins & Synapses) programme.
Kevin Cox, Imanova’s CEO, commented: “We are delighted to have been awarded strategic funding for the MIND-MAPS programme. We would like to thank the MRC and Dementias Platform UK (DPUK) for supporting the proposal and look forward to engaging more widely with the DPUK Imaging Network.”
MIND-MAPS is a pre-competitive consortium between Imanova, AbbVie, the MRC, the Hamamatsu Photonics PET centre, drawing on the therapy area expertise of the DPUK members.
The aim of the prog ...
The NIHR Brain Injury Healthcare Technology Co-operative is pleased to announce the second round of its second national competition. The seed funding call (up to £10,000) is for the early development of novel technology-based solutions applicable to the brain injury pathway, from prevention of injury all the way through to technologies for independent living. Applications are invited from academic institutions, NHS Trusts, third sector organisations and SME’s.
Cambridge, UK - Arecor's Prototype liquid glucagon product shows stability and commercial viability - Partnership with Innovate UK to accelerate pre-clinical asset towards proof-of-concept & first-in-human trials.
Oxford, UK – Glide Technologies, the pharmaceutical development and device company focused on the needle-free administration of solid dose formulations, today announced the successful completion of a funding round totalling £3.2 million ($4.0 million). The fundraising was supported by a number of existing investors.
OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.
This is an impromptu noticeboard to let people know about events, other things that are happening, perhaps lab equipment for sale etc. Just drop an email to us, firstname.lastname@example.org, and we will post.